Phase 1 trial of TSR-022 in combination with an anti-PD-1 antibody, TSR-042, in solid tumour patients

Trial Profile

Phase 1 trial of TSR-022 in combination with an anti-PD-1 antibody, TSR-042, in solid tumour patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2018

At a glance

  • Drugs TSR 022 (Primary) ; TSR 042 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms AMBER
  • Most Recent Events

    • 02 Aug 2018 According to a Tesaro media release, initial data from this trial has been submitted for inclusion in the Society for Immunotherapy of Cancer (SITC) annual meeting, November 2018, which includes results from lung cancer patients who have progressed on prior anti-PD-1 treatment.
    • 03 May 2018 According to a TESARO Inc. media release, data from tumor-specific expansion cohorts are expected to be presented at a medical meeting later in 2018.
    • 27 Feb 2018 According to a TESARO Inc. media release, this trial is enrolling three tumor specific cohorts and initial data is expected in 2H 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top